Novo’s Wegovy and Ozempic are among the most closely watched new medications in recent history, but face serious competition ...

J&J, AstraZeneca, Novo Nordisk and Roche are among the companies that might take a hit from the soon-to-be-enacted fees, ...

Anyone who’s looked at the market in the last couple of weeks will know that there were some events that shook investors.

We recently published an article titled Jim Cramer’s Game Plan: 15 Stocks in Focus. In this article, we are going to take a ...

The Novo Nordisk Foundation does not plan to step in to prop up a global health sector reeling from a freeze on U.S.-funded ...

The markets are likely to show some reactions to Donald Trump’s trade war, sparked by the US imposing sweeping tariffs on ...

Trump’s trade war, U.S. jobs report, and more ‘Big Tech’ earnings will be in focus this week. • Amazon looks set to deliver ...

On the earnings front, more results from major technology companies are due out this week. Highlighting the agenda is Google-parent Alphabet and e-commerce giant Amazon, which are set to unveil their ...

President Donald Trump said his administration will install 25% tariffs on goods from Canada and Mexico, ending the largely ...

Novo Nordisk said on Thursday it has not yet posted details about a new trial of its experimental next-generation obesity drug CagriSema, which it announced it would start after late-stage trial data ...

Novo Nordisk (NVO) said its popular diabetes drug Ozempic, or semaglutide, has been approved for the treatment of patients ...

Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type ...